Edwards Lifesciences To Acquire Innovalve Bio Medical Ltd., Acquisition Is Expected To Close By The End Of 2024; No Financial Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences (NYSE:EW) announced its acquisition of Innovalve Bio Medical Ltd., an early-stage TMVR company. The acquisition, expected to close by the end of 2024, aims to enhance Edwards' TMVR technologies and support long-term growth. Financial terms were not disclosed.
July 15, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences is acquiring Innovalve Bio Medical Ltd. to enhance its TMVR technologies. The acquisition is expected to close by the end of 2024, with no financial terms disclosed.
The acquisition of Innovalve Bio Medical Ltd. is likely to positively impact Edwards Lifesciences' stock in the short term as it enhances the company's TMVR technologies and supports long-term growth. The market generally views strategic acquisitions favorably, especially when they address large unmet needs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100